As Compound A is not highly optimized for use in vivo, this study suggests that ELOVL6 has significant potential as target for cancer intervention and sparks the interest in finding better chemical inhibitors with improved in vivo efficacy that could reverse the elongation phenotype in tumor tissue. The gene discussed is ELOVL6; the disease is neoplasm.